Fig. 1: Consort diagram.

Consort diagram is grouped by the three predefined age groups: ≤60 years (subgroup S1), 61–65 years (subgroup S2) and 66–70 years (subgroup S3). n/% numbers are from the intention-to-treat population of each age group. Light blue boxes indicate different trial sections or skipped therapy phases. Gray boxes summarize reasons for end of study between subsequent trial sections in the respective age groups S1, S2, and S3. For a detailed version of the consort diagram see Supplementary Fig. 1. ITT, intention-to-treat population; LEN, lenalidomide; MDS, myelodysplastic syndrome; MEL200, melphalan 200 mg/m²; ASCT, autologous blood stem cell transplantation; CR, complete response; AE, adverse event; PD, progressive disease.